Search

Search Results

1. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

   Background

   Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and...

   Manon Belhassen, Faustine Dalon, ... Eric Van Ganse in Respiratory Research

   Article Open access 04 May 2021
   

2. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

   Background

   In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced...

   Vincent Cottin, Luca Richeldi, ... Martin Kolb in Respiratory Research

   Article Open access 16 March 2021
   

3. Adalimumab/nintedanib

   in Reactions Weekly

   Article 23 October 2021

4. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

   Background

   Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged > 60 years who have several comorbidities. Nintedanib is an...

   Ian Glaspole, Francesco Bonella, ... Elisabeth Bendstrup in Respiratory Research

   Article Open access 26 April 2021
   

5. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

   Background

   Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to...

   James Patrick Finnerty, Aravind Ponnuswamy, ... Hafiz Kamil in BMC Pulmonary Medicine

   Article Open access 11 December 2021
   

6. Revisions of package inserts for efavirenz, nintedanib and ticagrelor

   in Reactions Weekly

   Article 26 March 2022

7. Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

   The article Nintedanib: A Review in Fibrotic Interstitial Lung Diseases, written by Yvette N. Lamb, was originally published electronically in...

   Yvette N. Lamb in Drugs

   Article Open access 29 May 2021

8. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

   Background

   Anti-angiogenic agents are reported to exert clinical activity in patients with epidermal growth factor receptor ( EGFR ) mutant non-small...

   Mariona Riudavets, Joaquim Bosch-Barrera, ... Margarita Majem in Clinical and Translational Oncology

   Article 22 July 2021
   

9. Nintedanib bremst Krankheitsprogression über ILD-Subgruppen hinweg

   Wolfgang Gesierich in Pneumo News

   Article 26 October 2021
   

10. Nintedanib/pirfenidone

    in Reactions Weekly

    Article 07 August 2021

11. Correction: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity

    Maurizio Cutolo, Emanuele Gotelli, ... Stefano Soldano in Arthritis Research & Therapy

    Article Open access 29 July 2023

12. Nintedanib

    in Reactions Weekly

    Article 10 April 2021

13. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

    Background

    Nintedanib is effective for treating idiopathic pulmonary fibrosis (IPF), but some patients may exhibit a suboptimal response and develop...

    Tang-Hsiu Huang, Chin-Wei Kuo, ... Sheng-Hsiang Lin in BMC Pulmonary Medicine

    Article Open access 15 May 2021
    

14. Nintedanib associated with proteinuria

    in Reactions Weekly

    Article 10 July 2021

15. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

    Introduction

    The safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) have been characterized using data from...

    Joseph A. Lasky, Gerard J. Criner, ... Luca Richeldi in Advances in Therapy

    Article Open access 07 August 2020
    

16. Nintedanib/pirfenidone

    in Reactions Weekly

    Article 02 January 2021

17. Nintedanib-induced glomerular microangiopathy: a case report

    Nintedanib, a triple tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and...

    Masataka Hasegawa, Atsuko Uehara, ... Yugo Shibagaki in CEN Case Reports

    Article 11 April 2020
    

18. Chronische PF-ILD: G-BA bescheinigt Zusatznutzen für Nintedanib

    Redaktion Facharztmagazine in Orthopädie & Rheuma

    Article 29 April 2021

19. Nintedanib

    in Reactions Weekly

    Article 31 October 2020

20. Nintedanib/pirfenidone

    in Reactions Weekly

    Article 05 December 2020